Ines-Regina Buth

Ines-Regina Buth

Ines-Regina Buth has a strong track record in advising both private and public companies in the healthcare and high-tech sectors, ranging from small start-ups to blue chip companies. During her career, she has successfully designed and implemented targeted communication plans for numerous corporate transactions (corporate partnerships, licensing deals, financing rounds, M&A, public listings, due diligences) and advised executives on reputation management, crisis communications and improving their day-to-day communication activities. She was actively involved in Schering’s listing on New York Stock Exchange (NYSE) and Micromet´s reverse merger into a NASDAQ-listed company.

Ines is an active member of the Life Science Committee of the Society of Investment Professionals in Germany (DVFA), which organizes and hosts the annual DVFA Life Science Conference in Frankfurt, Germany. She has an excellent industry network covering executives, investors, advisors, reporters and other opinion leaders.

Prior to founding akampion in late 2006, Ines has held various senior positions in investor relations and corporate communications, including Head of Investor Relations at Micromet AG / Inc. (now Amgen), Head of Investor Relations at LION bioscience AG and IR/PR positions with two global blue-chip companies (DaimlerChrysler AG, Schering AG – now Bayer Healthcare). She gained her first professional experience working in the corporate communications department at MLP AG and at Edelman Public Relations (corporate and financial communications).

Ines holds a Master’s Degree in Communication Management and North American Studies (Free University of Berlin, Germany) and is a Certified Biotechnology Analyst, CBA (Society of Investment Professionals in Germany, DVFA).